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We recently described a sensitive and specific assay that detects the fusion of HIV-1 virions to a broad range of target cells, including
primary CD4 cells. This assay involves the use of virions containing h-lactamase-Vpr (BlaM-Vpr) and the loading of target cells with CCF2,
a fluorogenic substrate of h-lactamase. Since Vpr strongly associates with the viral core, uncoating of the viral particle might be required for
effective cleavage of CCF2 by BlaM-Vpr. Here, we show that BlaM-Vpr within mature viral cores effectively cleaves CCF2, indicating that
this assay measures virion fusion independently of uncoating. We also show that wildtype and Nef-deficient HIV-1 virions fuse with
equivalent efficiency to HeLa-CD4 cells, SupT1 T cells, and primary CD4 T cells. Since Nef enhances cytoplasmic delivery of viral cores and
increases viral infectivity, these findings indicate that Nef enhances an early post-fusion event in the multistep process of viral entry. Possible
sites of Nef action include enlargement of the fusion pore, enhanced uncoating of viral particles, and more efficient passage of viral cores
through the dense cortical actin network located immediately beneath the plasma membrane.
D 2004 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus type 1 (HIV-1) princi-
pally infects CD4-expressing T lymphocytes, monocytes/
macrophages, dendritic cells, and microglial cells in vivo.
The entry of HIV-1 virions into these target cells requires
the initial interaction of the viral envelope protein with two
cell-surface receptors: CD4 and either CCR5 or CXCR4,
which function as coreceptors for entry of R5- and X4-
tropic viruses, respectively. The HIV-1 envelope protein
initiates viral entry by undergoing a succession of conforma-
tional changes triggered by its interplay with CD4 and the
coreceptors (Berger et al., 1999). These events lead to the0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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occurred, uncoating takes place. Although this process is
poorly understood, it likely involves the phosphorylation of
the viral capsid protein (Cartier et al., 1999), which may be
mediated by the catalytic subunit of the cellular protein
kinase A (Cartier et al., 2003) and facilitated by cyclophilin
A (Franke et al., 1994). Both viral uncoating and passage of
the viral cores through the dense cortical actin network are
required for delivery of the viral reverse transcription
complex/preintegration complex into the cytoplasm.
Among its many functions [for review, see (Arora et al.,
2002; Greene and Peterlin, 2002; Piguet and Trono, 1999)],
the HIV-1 Nef protein increases the infectivity of HIV-1 by
acting at an early step in the viral life cycle through both
CD4-dependent and CD4-independent mechanisms. These
changes in infectivity require the expression of Nef in the
virus-producing cells, even though the effects are man-
ifested in the subsequent target cells (Aiken and Trono,004) 36–44
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dependent changes are mediated through the downregula-
tion of surface CD4 expression in the virus-producing cell,
which leads either to more efficient detachment of virions or
to the release of virions containing greater quantities of the
surface gp120 envelope (Lama et al., 1999; Ross et al.,
1999).
The CD4-independent mechanism through which Nef
enhances HIV-1 infectivity is less well understood. Nef is
incorporated into HIV-1 viral particles (Aiken and Trono,
1995; Bukovsky et al., 1997; Miller et al., 1997; Welker et
al., 1996) but is cleaved by the HIV-1 protease, making a
role for intravirion full-length Nef less likely (Bukovsky et
al., 1997; Miller et al., 1997; Welker et al., 1996). Early
studies revealed that reverse transcription is impaired in
virions produced in the absence of Nef, suggesting that Nef
acts at an early step in the retroviral life cycle (Aiken and
Trono, 1995; Chowers et al., 1995; Schwartz et al., 1995).
The in vitro induction of endogenous reverse transcription
restores the infectivity of Nef-deficient virions (Khan et al.,
2001), although this reaction is associated with partial
disassembly of the HIV-1 core. Thus, an effect of Nef before
reverse transcription cannot be ruled out.
When viral entry is redirected through the endocytic
pathway by pseudotyping virions with the vesicular
stomatitis virus-G protein (VSV-G), the infectivity-enhanc-
ing effects of Nef are lost (Aiken, 1997; Chazal et al., 2001;
Luo et al., 1998). The density of either surface CD4 on the
target cells or envelope protein on virions also modulates
the extent to which Nef enhances viral infectivity (Tobiume
et al., 2001). These results argue that Nef acts at an early
step in the viral entry pathway before reverse transcription.
We recently demonstrated that Nef increases cytoplasmic
delivery of p24Gag (Schaeffer et al., 2001). However, these
results did not distinguish between an effect of Nef at the
level of virion fusion and at an early post-fusion step in the
entry pathway leading to effective delivery of capsid
proteins into the cytoplasm. The recent finding that Nef
expression increases the cholesterol content of the HIV-1
virion membrane (Zheng et al., 2001, 2003) coupled with
the fact that cholesterol can influence the entry of enveloped
viruses (Rawat et al., 2003) prompted us to examine
whether Nef enhances the fusion of HIV-1 virions to target
cells. Such an effect at the level of fusion could underlie the
Nef-dependent increase in cytosolic delivery of viral cores
we described previously (Schaeffer et al., 2001).
To test whether Nef alters the fusion of HIV-1 virions, we
developed a virion-based fusion assay (Cavrois et al., 2002,
2004). This assay is based on the incorporation of a h-
lactamase-Vpr (BlaMVpr) protein chimera into the virion
and the subsequent transfer of this chimera into the target
cell as a result of fusion. Successful transfer can be
monitored by the enzymatic cleavage of the CCF2-AM
dye, a fluorescent substrate of h-lactamase (BlaM), loaded
into the target cells. Cleavage of the h-lactam ring in CCF2
by h-lactamase alters the fluorescence emission spectrum ofthe dye from green (520 nm) to blue (447 nm) (Zlokarnik et
al., 1998). This change can be detected at the single-cell
level by fluorescence microscopy or flow cytometry. Of
note, this assay detects HIV-1 virion fusion and not virion
endocytosis (Cavrois et al., 2002). However, since Vpr
strongly associates with the p6 component of Gag, the
BlaM-Vpr chimera likely resides within the viral core. In
such a scenario, particle uncoating might be required for
cleavage of CCF2 by BlaM-Vpr. If so, the virion-based
assay would be affected by events altering both fusion and
uncoating.
In this study, we determined whether uncoating of the
viral particle is required to generate a positive signal in the
fusion assay. We also assessed whether the enhanced
delivery of cytoplasmic p24Gag and increased infectivity
induced by Nef reflect events occurring at the level of
fusion.Results
The virion-based fusion assay detects fusion independently
of viral uncoating
The BlaM-Vpr chimera is incorporated into the virion
through the interaction of Vpr with the p6 component of
Gag (Paxton et al., 1993). This physical association suggests
that BlaM-Vpr may reside in the viral core. Studies were
undertaken to investigate the localization of BlaM-Vpr
within HIV-1 virions. As expected, gp41 was not detected in
these isolated HIV-1 cores, and both subunits of reverse
transcriptase (p51 and p66) and Vpr remained associated
with the core (Fig. 1A). As previously reported (Welker et
al., 2000), only a fraction with p24Gag purified with the
cores. Our results indicate that BlaM-Vpr remains associ-
ated with the HIV-1 cores.
To determine if BlaM-Vpr associated with the HIV-1
core can cleave CCF2, purified cores were incubated for 3
or 6 h at room temperature with the nonesterified version of
CCF2 (CCF2-AF, Invitrogen). The ratio of blue to green
fluorescence increased in the presence of the HIV-1 cores
(Fig. 1B). To ensure that the BlaM activity in these core
preparations did not result from a enzyme leakage or
contamination by uncoated cores, we compared the BlaM
activity in intact cores and in cores disassembled by
sonication. BlaM activity was identical in both cases (Fig.
1B). To control for the efficiency of core disassembly, we
measured BlaM activity released from the sonicated cores
into the supernatant following centrifugation (Fig. 1C).
BlaM activity was only detected in the supernatant of the
sonicated cores, not the intact cores, indicating that
sonication was effective in disassembling HIV-1 cores.
Finally, to control for the integrity of untreated cores after a
6-h incubation at room temperature, we determined the
percentage of p24Gag present in the pellet after high-speed
centrifugation of core-containing suspensions. More than
Fig. 1. Analysis of the HIV-1 virions and cores. (A) Localization of BlaM-Vpr in NL4-3 viral particles. NL4-3 cores were purified from supernatants of 293T
cell cultures transfected with the indicated proviral and BlaM-Vpr DNAs. The content of the purified core was compared to the content of intact virions by
immunoblot analysis with anti-RT (Szilvay et al., 1992), anti-gp41 (Gorny et al., 1989), anti-p24Gag (Coulter), and anti-Vpr (Jenkins et al., 1998) antibodies.
Note the presence of BlaM-Vpr in HIV-1 core. BlaM-Vpr and Vpr migrate at 41 and 11 kDa, respectively. (B) Measurement of BlaM activity associated with
purified cores. Purified cores were sonicated or left intact and incubated with CCF2-FA for 3 or 6 h at room temperature. The increase in the ratio of blue to
green fluorescence was similar in both preparations. (C) Measurement of BlaM activity released into the supernatant. Untreated or sonicated cores were
pelleted, and BlaM activity released into the supernatant was measured after 3 and 6 h of incubation with CCF2-FA at room temperature. BlaM activity was
found only in the supernatant of cultures containing sonicated cores.
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were untreated, but no pelletable p24Gag was observed in
the negative control (HIV-1 cores treated with 0.1% Triton
X-100; data not shown). These results indicate that BlaM-
Vpr associated with the HIV-1 core can cleave CCF2.
Therefore, uncoating is not required to generate a positive
signal in the HIV-1 virion-based fusion assay.
HIV-1 virions produced in presence and in absence of Nef
fuse equivalently to HeLa-CD4 cells
To further study the precise mechanism by which Nef
increases the cytoplasmic delivery of viral cores and
enhances infectivity, wildtype and Nef-deficient virions
containing BlaM-Vpr were produced. First, we assessed
whether equivalent amounts of BlaM-Vpr were incorporated
into these virions (Fig. 2A). Pelleted virions were lysed and
immunoblotted with rabbit polyclonal anti-Vpr (Jenkins et
al., 1998) or mouse monoclonal anti-p24Gag antibodies for
standardization of the virion preparations. The BlaM-Vpr
chimera was comparably incorporated into wildtype and
Nef-deficient virions (Fig. 2A).
Next, we investigated the fusion of wildtype and Nef-
deficient X-4 tropic virions to HeLa-CD4 cells (Cavrois et
al., 2002). The cells were plated in chamber slides and
infected for 2 h at 37 8C in the presence or absence of
AMD3100, an inhibitor of CXCR4-dependent virion entry
(Fig. 2B). CCF2-AM, the membrane-permeable ester form
of the BlaM substrate, was then loaded into target cells, and
enzymatic cleavage was allowed to proceed for 7 h at room
temperature. The cells were then fixed in 1.2% parafor-
maldehyde and analyzed by fluorescence microscopy (Fig.2B). As expected, no bblueQ cells, indicative of HIV-1
virion fusion, were detected in either the mock-infected or
AMD3100-treated samples. However, comparable numbers
of blue cells were detected in cultures infected with
wildtype or Nef-deficient virions. Similar results were
obtained with R5-tropic virions in HeLa-CD4 cells
expressing CCR5 (data not shown). These findings indicate
that Nef does not influence the fusion of HIV-1 virions to
HeLa-CD4 cells.
Nef enhances HIV-1 infectivity but not fusion in human
SupT1 T cells
We next assessed the fusion of wildtype and Nef-
deficient virions to human CD4+ SupT1 cells. To ensure
that the fusion reaction was measured within the dynamic
range of the assay, SupT1 cells were infected with serial
dilutions of the two viral stocks. The effects of Nef on
infectivity of HIV-1 were assessed in parallel within the
same infected population of cells. Fusion was measured by
flow cytometry 2 h after infection, and productive viral
infection of these cells was assessed 48 h later by
intracellular immunostaining with FITC-conjugated anti-
p24Gag antibodies (Cavrois et al., 2002). In cells inoculated
with 100 ng of p24Gag (Fig. 3A), slightly more Nef-deficient
virions than wildtype virions fused to SupT1 cells (36%
versus 28%). Conversely, fewer target cells were produc-
tively infected by Nef-deficient virions than by wildtype
virions (10.5% versus 25%). At all of the dilutions tested,
despite a consistent decrease in the number of productively
infected cells, fusion of Nef-deficient virions to SupT1
target cells was either equivalent to or slightly better than
Fig. 2. Virions produced in the absence of Nef are not impaired in their ability to fuse to HeLa-CD4 cells. (A) Incorporation of BlaM-Vpr into wildtype or DNef
NL4-3 virions. Virions were collected by ultracentrifugation of supernatants from cultures of 293T cells transfected with the indicated proviral and BlaM-Vpr
DNAs. The levels of p24Gag were used to standardize virion loading. Note the presence of equivalent amounts of the BlaM-Vpr chimeric protein in the
wildtype and DNef virions and the comparability of virion p24Gag and Vpr content. (B) Cultures of HeLa-CD4 cells were mock-infected or infected for 2 h with
wildtype NL4-3 or DNef NL4-3 virions containing BlaM-Vpr (200 ng of p24Gag). The CXCR4-specific inhibitor of entry, AMD3100 (250 nM), was added 1 h
before infection. The images correspond to an overlay of frames captured after fluorophore excitation with light at 495 and 395 nm using the appropriate filter
sets. Note the presence of comparable numbers of blue HeLa-CD4 cells, indicative of virion fusion, in cultures infected with wildtype or DNef virions.
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to enhance virion infectivity through effects at the level of
fusion in SupT1 cells.
Nef enhances HIV-1 infectivity at a post-fusion step in
primary T cells
Although Nef exerts only a modest effect on the ability
of HIV-1 to spread in T-cell lines, it consistently enhances
HIV-1 replication in primary CD4 T lymphocytes, partic-
ularly when the cells are stimulated after infection (Miller
et al., 1994; Spina et al., 1994). Thus, we assessed the
effects of Nef on viral fusion in unactivated peripheral
blood lymphocytes (Fig. 4). An aliquot of these cell
cultures was stimulated with phytohemagglutinin (5 Ag/ml)
and interleukin-2 (20 IU/ml) to allow completion of the
retroviral life cycle. Productive viral infection was assessed
4 days later by intracellular immunostaining with FITC-
conjugated anti-p24Gag antibodies (Fig. 4). To identify T
lymphocytes, the fusion assay was combined with an anti-
CD3 immunostaining step. As expected, the addition of
AMD3100, the X4-tropic HIV-1 inhibitor, blocked both
the fusion and replication of NL4-3 viruses, while treat-
ment with AZT had no inhibitory effect on fusion but
blocked productive infection. Similar levels of fusion were
observed with wildtype and Nef-deficient virions (1.39%
versus 1.73%). However, in the same cultures after 4 days
of stimulation that allowed a second round of replication to
occur, Nef significantly increased the number of produc-
tively infected cells (4.68% versus 1.15%). Similar resultswere obtained with phytohemagglutinin-activated periph-
eral blood leukocytes; however, the Nef phenotype was
less pronounced (data not shown), consistent with previous
studies (Spina et al., 1994). These findings indicate that
Nef does not enhance HIV-1 infectivity in primary CD4 T
lymphocytes by increasing virion fusion to these cellular
targets.Discussion
This study shows that the HIV-1 virion-based fusion
assay measures fusion independently of viral particle
uncoating, as demonstrated by the ability of isolated
HIV-1 cores containing BlaM-Vpr to readily cleave the
CCF2 fluorescent substrate. We also showed that the
enhanced cytoplasmic delivery of viral cores produced by
Nef does not reflect changes at the level of virion fusion in
primary CD4 T lymphocytes or in the various cell lines we
studied.
In contrast to our findings, a recent study indicated that
Nef increases HIV-1 fusion to MAGI R5 cells by twofold
(Day et al., 2004). These results could reflect the type of
target cells used. Some cell lines, including MAGI cells,
have endogenous BlaM activity, which likely results from
a leakage of the prokaryote promoter of the plasmid
introduced in these cells (Cavrois et al., 2004). Such
activity might have altered the position of the bblue cellQ
gate and led to a misinterpretation of the data. However,
our findings agree with Tobiume et al. (2003), who found
Fig. 3. Effects of Nef on HIV-1 virion fusion and infectivity in human SupT1 T cells. SupT1 cells (5  105) were mock-infected or infected with serial dilutions
of wildtype or DNef NL4-3 virions containing BlaM-Vpr. After 2 h, an aliquot of cells was removed and analyzed in the fusion assay by multiparameter flow
cytometry using a violet laser to excite CCF2. The remaining cells were incubated for 48 h at 37 8C. Productive HIV-1 infection was quantified by intracellular
staining with FITC-conjugated anti-p24Gag antibodies. (A) Representative data from SupT1 cells infected with 100 ng of p24Gag. Percentages of cells
displaying increased blue fluorescence or increased FITC fluorescence are shown in the inset of the red gate. (B) Levels of fusion and productive infection were
assessed over a broad range of wildtype and DNef viral inputs. Each infection was performed in triplicate with the indicated viral input. Error bars indicate
standard deviations.
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virions to HeLa-CD4 or MT4 cells. Therefore, Nef appears
to act at an early post-fusion step in the viral entry
pathway.
Since our virion-based assay measures fusion independ-
ently of uncoating, one possibility is that Nef leads to more
efficient virion uncoating. However, this scenario is not
likely, since Nef does not appear to alter the stability of
viral cores in vitro (Forshey and Aiken, 2003). Alterna-
tively, Nef may facilitate the passage of viral cores through
the dense subcortical actin network beneath the plasma
membrane (Campbell and Hope, 2004). Trapping of Nef-
deficient virions in this actin network could lead to
fractionation of capsid proteins in the membrane- and
vesicle-rich pellet after ultracentrifugation. This might
account for diminished cytoplasmic delivery of p24Gag in
the absence of Nef (Schaeffer et al., 2001). The fact thatVSV-G pseudotyping relieves the requirement for Nef
could be explained by the ability of endosomes to traffic
through the cortical actin network. However, this model
would not appear to account for the influence of the density
of either surface CD4 on target cells or envelope protein on
virions on Nef enhancement of viral infectivity described
by Tobiume et al. (2001).
A third possibility is that Nef acts after fusion but
before uncoating by facilitating enlargement of the fusion
pore. Since the plasma membrane and the subcortical
actin network are closely linked, drug-induced destabili-
zation of this network could alter the organization of the
plasma membrane, which could in turn enlarge the fusion
pore and enhance the passage of HIV-1 cores into the
cell. Enlargement of the fusion pore could also be
affected by high concentrations of CD4 or coreceptor in
the target cells or envelope on the virions, which would
Fig. 4. Nef enhances HIV-1 infectivity at a post-fusion step in primary human T-cells. Unactivated peripheral blood leukocytes (2  106) were incubated with
wildtype or DNef NL4-3 virions (400 ng of p24Gag) containing BlaM-Vpr in the presence or absence of 250 nM AMD3100 or 10 AM AZT. After CCF2-AM
dye loading and incubation for 12 h at room temperature to allow BlaM degradation of the substrate, the cells were washed and immunostained with anti-CD3
antibodies. Fusion events were analyzed in the CD3+ subpopulation of lymphocytes. To complete the HIV-1 replication cycle, an aliquot of the cells was
incubated for 4 days in the presence of 5 Ag/ml phytohemagglutinin (PHA) and 20 IU/ml interleukin-2 (IL-2). Productive infection was then assessed by
intracellular immunostaining with anti-p24Gag antibodies and with anti-CD3. (A) FACS plots of a representative data set. The percentage of CD3+ cells
displaying increased blue fluorescence (fusion) or increased anti-p24Gag FITC immunofluorescence (productive viral infection) are shown in the red gates; the
percentages of cells in these gates are shown in the inset. (B) Histogram analysis of the representative experiment. Error bars denote standard deviations.
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Under these conditions, dependence on Nef might
decrease, as found by Tobiume et al. (2001). The higher
cholesterol content of wildtype virions compared to Nef-
deficient virions (Zheng et al., 2001, 2003) might also
contribute to more effective opening of the fusion pore,
as cholesterol has been proposed as a key factor
facilitating the growth of the fusion pore (Razinkov and
Cohen, 2000).
Although the precise site of Nef action remains unclear,
our studies further refine its site of action to an early post-
fusion step that limits the effective delivery of HIV-1 cores
into the cytoplasm. Nef-mediated bypass of this block
appears to be required for effective reverse transcription and
the resultant increase in viral infectivity.Materials and methods
Viral production
HIV-1 virions containing BlaM-Vpr were produced by
cotransfection of 293T cells (plated in 175 cm2 flasks) with
pNL4-3 proviral DNA (60 Ag) or pNL4-3DNef, pCMV-
BlaM-Vpr (20 Ag), and pAdVAntage vectors (10 Ag)
(Promega). After 24 h of culture at 37 8C, the virus-
containing supernatant was centrifuged at low speed to
remove cellular debris and then ultracentrifuged at 72,000 
g for 90 min at 4 8C to sediment viral particles. The virion-
enriched pellet was resuspended in Dulbecco’s modified
Eagle medium (DMEM) and aliquoted for storage at 80
8C. All transfections were performed with calcium phos-
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p24Gag content, measured in an enzyme-linked immuno-
sorbent assay (NEN Life Science Products).
Purification of HIV-1 cores
HIV-1 cores were purified as described (Welker et al.,
2000) with minor modifications. Viral particles in the
supernatant of 293T cells transfected as described above
were concentrated by centrifugation (100,000 g for 2 h at 4
8C) through a cushion formed with 2 ml of 6% iodixanol
(Optiprep, Gibco BRL) diluted in phosphate-buffered saline
(PBS). The pellet was washed and resuspended in 120 Al of
PBS. Subsequently, 40 Al of this viral suspension was mixed
with an equal volume of 200 mM NaCl, 100 mM
morphoinepropanesulfonic acid (MOPS; pH 7.0). Virions
were either left intact or lysed by adding Triton X-100 (final
concentration, 0.5%). Intact virions or HIV-1 cores were
recovered by centrifugation at 13,800  g for 8 min at 4 8C.
The pellets were washed twice in 100 mM NaCl and 50 mM
MOPS (pH 7.0), and protein composition was analyzed by
immunoblotting with antibodies against gp41, reverse tran-
scriptase (p66RT or p51RT), or Vpr.
Analysis of the b-lactamase activity of BlaM-Vpr
HIV-1 cores purified from 240 Al of concentrated virion
preparations were diluted in 4 ml of 100 mM NaCl and 50
mM MOPS (pH 7.0). Half of the resulting suspension was
sonicated on ice (10-s pulses for 5 min), and half was kept at
4 8C. CCF2-FA, the fluorescent substrate of BlaM (Invi-
trogen), was then added to both suspensions (final concen-
tration, 5 AM). BlaM activity was measured after 3 and 6 h
of incubation at room temperature by determining the ratio
of blue to green fluorescence with a microplate reader
(FLEX Station, Molecular Probes) (excitation: 405 nm;
emission: blue, 460 nm, green, 530 nm). To control for the
efficiency of core disassembly, the suspension was centri-
fuged at 13,800  g for 8 min at 4 8C to pellet the cores.
The BlaM activity released into the supernatant was then
measured after addition of 5 AM CCF2-FA to the super-
natant and incubation for 3 and 6 h at room temperature. To
control for the integrity of HIV-1 cores after a 6-h
incubation, we measured the percentage of pelletable
p24Gag after centrifugation at 13,800  g for 8 min at 4
8C. As a negative control, viral cores were incubated with
0.1% Triton X-100 for 6 h at room temperature. The p24Gag
content of both the supernatant and the pellet was
determined by enzyme-linked immunosorbent assay.
Virion-based fusion assay
Infection conditions were adapted to the requirements of
each target cell population. The day before analysis, HeLa-
CD4 cells (3  105) were plated on a cover slide (Falcon
CultureSlide, Becton Dickinson) and infected with HIV-1virions containing BlaM-Vpr (200 ng of p24Gag) at 37 8C for
3 h. SupT1 cells (5  105) were infected with virions
containing BlaM-Vpr (25 to 200 ng of p24Gag in 100 Al).
Unactivated peripheral blood leukocytes (2  106) were
infected with p24Gag (400 ng in 100 Al), washed once in CO2-
independent DMEM (GIBCO BRL) to remove free virions,
and loaded with CCF2-AM dye according to the manufac-
turer’s instructions (Invitrogen). After two washes with
DMEM, the cells were incubated for 7 to 16 h at room
temperature in 200 Al of DMEM supplemented with 10%
fetal bovine serum (FBS) and 2.5 mM probenecid, a
nonspecific inhibitor of anion transport (Sigma). The cells
were then washed once in DMEM and fixed in 1.2%
paraformaldehyde overnight.
The change in emission fluorescence of CCF2 dye after
cleavage by BlaM-Vpr was monitored with a three-laser
Vantage SE flow cytometer (Becton Dickinson, San Jose,
CA). CCF2 was excited by 200 mW of 406.7 nm light from
a krypton laser (Coherent). Blue emission was detected with
an HQ455/50 filter and green emission with an HQ545/90
BP filter; light splitting was performed with a 505 SP filter.
Data were collected with CellQuest and analyzed with
FlowJo software (Treestar, San Carlos, CA). All filters were
from Chroma Technology (Brattleboro, VT). In some
experiments, digital images were obtained with a Nikon
TE300 microscope equipped with a Hammamatsu ORCA II
dual-scan, cooled CCD camera. CCF2 was excited with
light from a mercury arc lamp filtered through Chroma
D395X or D485X filters. Images were captured and
processed with Universal Imaging MetaMorph (v4.6) and
Adobe Photoshop.
Immunostaining
When the assay was applied to heterogeneous cell
populations such as peripheral blood leukocytes, an
immunostaining step was performed as described (Cavrois
et al., 2004) before fixation of the cells to allow phenotyping
of the subpopulations in which fusion had occurred.
Standard immunostaining conditions were employed.
Briefly, the cells were washed twice in staining buffer
(PBS-2% FBS) and incubated for 30 min at room temper-
ature with anti-CD3-APCCy7 diluted 1:20 in staining
buffer. After two washes, the cells were fixed and analyzed
by multiparameter flow cytometry.
Intracellular anti-p24Gag staining
After two washes in PBS-2% FBS, the cells were
permeabilized by incubation at room temperature for 30
min in PermeaFix (Ortho Diagnostic System, Raritan, NJ),
washed twice, and incubated for 30 min at room temperature
with anti-p24Gag antibody (KC57) conjugated to FITC
(1:20) and anti-CD3 conjugated to PE (1:100). After two
washes, the cells were fixed and analyzed by multiparameter
flow cytometry.
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